Wanbury Limited
Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India and internationally. The company offers formulations for anti-infectives, pain and analgesics, respiratory, gastroenterology, gynecology, rheumatology, and central nervous system, as well as for vitamins, minerals, and nutrition. It also provides API products for antidiabetics, antihistamines,… Read more
Wanbury Limited (WANBURY) - Net Assets
Latest net assets as of September 2025: ₹1.07 Billion INR
Based on the latest financial reports, Wanbury Limited (WANBURY) has net assets worth ₹1.07 Billion INR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₹4.57 Billion) and total liabilities (₹3.49 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₹1.07 Billion |
| % of Total Assets | 23.49% |
| Annual Growth Rate | -2.77% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 69.93 |
Wanbury Limited - Net Assets Trend (2006–2025)
This chart illustrates how Wanbury Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Wanbury Limited (2006–2025)
The table below shows the annual net assets of Wanbury Limited from 2006 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | ₹592.72 Million | +112.13% |
| 2024-03-31 | ₹279.41 Million | +185.15% |
| 2023-03-31 | ₹-328.16 Million | -40.12% |
| 2022-03-31 | ₹-234.20 Million | +85.01% |
| 2021-03-31 | ₹-1.56 Billion | -8.92% |
| 2020-03-31 | ₹-1.43 Billion | +31.45% |
| 2019-03-31 | ₹-2.09 Billion | -13.32% |
| 2018-03-31 | ₹-1.85 Billion | -20.49% |
| 2017-03-31 | ₹-1.53 Billion | +6.10% |
| 2016-03-31 | ₹-1.63 Billion | +7.88% |
| 2015-03-31 | ₹-1.77 Billion | -7.35% |
| 2014-03-31 | ₹-1.65 Billion | -675.06% |
| 2013-03-31 | ₹-212.95 Million | -129.95% |
| 2012-03-31 | ₹711.13 Million | -32.26% |
| 2011-03-31 | ₹1.05 Billion | -45.45% |
| 2010-03-31 | ₹1.92 Billion | +21.46% |
| 2009-03-31 | ₹1.58 Billion | +22.71% |
| 2007-03-31 | ₹1.29 Billion | +27.66% |
| 2006-03-31 | ₹1.01 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Wanbury Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 108352500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₹327.70 Million | 55.29% |
| Other Components | ₹1.35 Billion | 227.52% |
| Total Equity | ₹592.72 Million | 100.00% |
Wanbury Limited Competitors by Market Cap
The table below lists competitors of Wanbury Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Haivision Systems Inc
PINK:HAIVF
|
$51.02 Million |
|
Ofuna Technology Co., Ltd.
TWO:4577
|
$51.02 Million |
|
Comstock Holding Companies Inc
NASDAQ:CHCI
|
$51.03 Million |
|
STV GROUP PLC LS -50
F:3YC
|
$51.03 Million |
|
Bygg Partner i Dalarna Holding AB
ST:BYGGP
|
$51.00 Million |
|
Wir Asia Tbk PT
JK:WIRG
|
$50.99 Million |
|
QUADPACK INDUSTRIES EO 1
F:4VP
|
$50.99 Million |
|
Independent Bond
CO:IIVBON
|
$50.99 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Wanbury Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 279,414,000 to 592,718,000, a change of 313,304,000 (112.1%).
- Net income of 305,301,000 contributed positively to equity growth.
- Share repurchases of 250,000 reduced equity.
- New share issuances of 250,000 increased equity.
- Other comprehensive income decreased equity by 179,638,000.
- Other factors increased equity by 187,641,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₹305.30 Million | +51.51% |
| Share Repurchases | ₹250.00K | -0.04% |
| Share Issuances | ₹250.00K | +0.04% |
| Other Comprehensive Income | ₹-179.64 Million | -30.31% |
| Other Changes | ₹187.64 Million | +31.66% |
| Total Change | ₹- | 112.13% |
Book Value vs Market Value Analysis
This analysis compares Wanbury Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 14.21x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 2.72x to 14.21x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-03-31 | ₹91.16 | ₹247.75 | x |
| 2007-03-31 | ₹97.01 | ₹247.75 | x |
| 2009-03-31 | ₹102.66 | ₹247.75 | x |
| 2010-03-31 | ₹125.81 | ₹247.75 | x |
| 2011-03-31 | ₹84.22 | ₹247.75 | x |
| 2012-03-31 | ₹30.23 | ₹247.75 | x |
| 2013-03-31 | ₹-27.59 | ₹247.75 | x |
| 2015-03-31 | ₹-97.12 | ₹247.75 | x |
| 2016-03-31 | ₹-94.53 | ₹247.75 | x |
| 2017-03-31 | ₹-73.66 | ₹247.75 | x |
| 2018-03-31 | ₹-77.86 | ₹247.75 | x |
| 2019-03-31 | ₹-88.23 | ₹247.75 | x |
| 2020-03-31 | ₹-59.86 | ₹247.75 | x |
| 2021-03-31 | ₹-62.48 | ₹247.75 | x |
| 2022-03-31 | ₹-7.25 | ₹247.75 | x |
| 2023-03-31 | ₹-1.88 | ₹247.75 | x |
| 2024-03-31 | ₹8.44 | ₹247.75 | x |
| 2025-03-31 | ₹17.43 | ₹247.75 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Wanbury Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 51.51%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 5.09%
- • Asset Turnover: 1.45x
- • Equity Multiplier: 6.98x
- Recent ROE (51.51%) is above the historical average (5.61%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | 10.61% | 9.86% | 0.56x | 1.93x | ₹6.16 Million |
| 2007 | 16.13% | 14.48% | 0.45x | 2.48x | ₹79.14 Million |
| 2009 | -21.31% | -13.23% | 0.29x | 5.53x | ₹-472.21 Million |
| 2010 | 4.55% | 1.78% | 0.59x | 4.36x | ₹-100.66 Million |
| 2011 | -67.73% | -21.63% | 0.51x | 6.15x | ₹-961.58 Million |
| 2012 | -87.50% | -10.07% | 0.48x | 18.24x | ₹-433.39 Million |
| 2013 | 0.00% | -19.00% | 0.59x | 0.00x | ₹-824.34 Million |
| 2014 | 0.00% | -19.30% | 1.09x | 0.00x | ₹-659.68 Million |
| 2015 | 0.00% | 1.28% | 0.63x | 0.00x | ₹225.98 Million |
| 2016 | 0.00% | -1.69% | 1.11x | 0.00x | ₹117.30 Million |
| 2017 | 0.00% | 14.45% | 1.04x | 0.00x | ₹773.43 Million |
| 2018 | 0.00% | -8.70% | 1.35x | 0.00x | ₹-135.40 Million |
| 2019 | 0.00% | -6.42% | 1.35x | 0.00x | ₹-39.20 Million |
| 2020 | 0.00% | 17.78% | 1.30x | 0.00x | ₹788.07 Million |
| 2021 | 0.00% | -3.26% | 1.34x | 0.00x | ₹30.19 Million |
| 2022 | 0.00% | 15.94% | 1.45x | 0.00x | ₹838.16 Million |
| 2023 | 0.00% | -2.09% | 1.64x | 0.00x | ₹-97.80 Million |
| 2024 | 200.26% | 9.74% | 1.67x | 12.29x | ₹531.62 Million |
| 2025 | 51.51% | 5.09% | 1.45x | 6.98x | ₹246.03 Million |
Industry Comparison
This section compares Wanbury Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $12,445,167,922
- Average return on equity (ROE) among peers: 14.66%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Wanbury Limited (WANBURY) | ₹1.07 Billion | 10.61% | 3.26x | $51.00 Million |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $802.45 Million | 7.70% | 1.12x | $11.20 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $1.12 Billion | 12.32% | 2.74x | $149.72 Million |
| Abbott India Limited (ABBOTINDIA) | $42.33 Billion | 33.41% | 0.40x | $1.59 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $15.68 Billion | 32.33% | 0.16x | $1.46 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $7.20 Billion | -0.56% | 3.88x | $123.83 Million |
| Albert David Limited (ALBERTDAVD) | $2.44 Billion | 9.06% | 0.40x | $15.85 Million |
| Alivus Life Sciences Limited (ALIVUS) | $28.17 Billion | 17.24% | 0.21x | $333.13 Million |
| Alkem Laboratories Limited (ALKEM) | $23.74 Billion | 20.90% | 0.71x | $2.41 Billion |
| Alpa Laboratories Limited (ALPA) | $56.73 Million | 0.53% | 2.47x | $5.55 Million |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $2.91 Billion | 13.70% | 0.25x | $77.60 Million |